ERCC1 and lung cancer: Indeed, small-molecule inhibitors that block the interaction between ERCC1 and XPF—two key factors in the nucleotide excision repair (NER) pathway—can enhance the cytotoxic effects of cisplatin and mitomycin C in lung cancer and colorectal carcinoma cells (42, 43).